Covered recipient · General Payments record
CHELSEY SMITH
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2023–2025
$1,524.34
- Reported across 33 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $404.20 | 17 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $177.03 | 12 |
| Galderma Laboratories, L.P. | $112.13 | 1 |
| REVANCE THERAPEUTICS, INC. | $99.74 | 3 |
| Cipher Pharmaceuticals US LLC | $15.30 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $10.26 | 02/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486168 | CMS |
| ABBVIE INC. | $7.17 | 02/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486174 | CMS |
| ABBVIE INC. | $26.89 | 02/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486180 | CMS |
| ABBVIE INC. | $22.13 | 02/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486186 | CMS |
| ABBVIE INC. | $22.19 | 05/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486191 | CMS |
| ABBVIE INC. | $4.04 | 05/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486200 | CMS |
| ABBVIE INC. | $5.35 | 07/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486206 | CMS |
| ABBVIE INC. | $19.03 | 07/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486212 | CMS |
| ABBVIE INC. | $17.85 | 08/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486218 | CMS |
| ABBVIE INC. | $16.99 | 09/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486227 | CMS |
| ABBVIE INC. | $12.79 | 10/23/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486233 | CMS |
| ABBVIE INC. | $12.34 | 11/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203486239 | CMS |
| Cipher Pharmaceuticals US LLC | $15.30 | 11/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1250590581 | CMS |
| Galderma Laboratories, L.P. | $112.13 | 03/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234825332 | CMS |
| REVANCE THERAPEUTICS, INC. | $52.49 | 06/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1251200163 | CMS |
| REVANCE THERAPEUTICS, INC. | $17.32 | 07/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1251200165 | CMS |
| REVANCE THERAPEUTICS, INC. | $29.93 | 09/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1251200167 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.